What is the global market size of Vaccine Adjuvants Market?

Global Vaccine Adjuvants Market size was valued at USD 0.9 billion in 2021 and is poised to grow from USD 1.31 billion in 2022 to USD 2.90 billion by 2030, growing at a CAGR of 11.9% during the forecast period (2023-2030).

Global Vaccine Adjuvants Companies

Global Vaccine Adjuvants Market Competitive Landscape

Vaccine Adjuvants Market Top Player’s Company Profiles

CSL Limited (Australia)

GlaxoSmithKline plc (United Kingdom)

Novavax, Inc. (US)

SEPPIC (France)

Agenus Inc. (US)

InvivoGen (US)

Brenntag Biosector (Denmark)

Avanti Polar Lipids, Inc. (US)

Vaxine Pty Ltd. (Australia)

SPI Pharma (US)

OZ Biosciences (France)

CureVac AG (Germany)

Adjuvatis (France)

Advanced BioAdjuvants Corporation (US)

Adjuvance Technologies Inc. (US)

SDA Bio (Italy)

Bio Products Laboratory Ltd. (United Kingdom)

GSK Vaccines GmbH (Germany)

Mucosis B.V. (Netherlands)

NanoBio Corporation (US)

Vaccine Adjuvants Market

FAQs

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).

The global vaccine adjuvants market is characterized by a diverse range of companies striving to innovate and meet the growing demand for adjuvant products. Market players are engaged in extensive research and development activities to enhance the effectiveness and safety of adjuvants. Additionally, partnerships, collaborations, and acquisitions are common strategies adopted by companies to strengthen their market position. The competitive environment fosters a continuous drive for technological advancements, improved manufacturing processes, and the development of novel adjuvant formulations, contributing to the overall growth and competitiveness of the market. 'CSL Limited (Australia)', 'GlaxoSmithKline plc (United Kingdom)', 'Novavax, Inc. (US)', 'SEPPIC (France)', 'Agenus Inc. (US)', 'InvivoGen (US)', 'Brenntag Biosector (Denmark)', 'Avanti Polar Lipids, Inc. (US)', 'Vaxine Pty Ltd. (Australia)', 'SPI Pharma (US)', 'OZ Biosciences (France)', 'CureVac AG (Germany)', 'Adjuvatis (France)', 'Advanced BioAdjuvants Corporation (US)', 'Adjuvance Technologies Inc. (US)', 'SDA Bio (Italy)', 'Bio Products Laboratory Ltd. (United Kingdom)', 'GSK Vaccines GmbH (Germany)', 'Mucosis B.V. (Netherlands)', 'NanoBio Corporation (US)'

One key driver for the growth of the global vaccine adjuvants market is the increasing focus on the development of innovative vaccines against emerging and existing diseases. As new infectious diseases continue to emerge and existing ones evolve, there is a growing need for vaccines with enhanced immunogenicity and long-lasting efficacy. Adjuvants play a crucial role in boosting the immune response and improving vaccine effectiveness. The demand for vaccine adjuvants is driven by the imperative to develop advanced vaccines that can effectively combat these evolving and challenging diseases.

The rising need for innovative adjuvant formulations is a significant trend in the world market for vaccine adjuvants. As there is a greater need for effective vaccines, researchers are creating and implementing cutting-edge adjuvant technologies to improve vaccine efficacy and durability. The use of cutting-edge adjuvant substances and delivery technologies that promote potent immune responses while minimising negative effects is included in this.

North America dominated the global vaccine adjuvants market. The United States is a developed country with a substantial population, resulting in a high demand for immunization and vaccine-related products. Additionally, the country experiences a large influx of travelers, which further emphasizes the importance of immunization to ensure public health and safety. Furthermore, the United States has a well-established healthcare infrastructure and favorable government initiatives that support immunization programs, thereby driving the demand for vaccine adjuvants.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route) - Industry Forecast 2024-2031

Global Vaccine Adjuvants Market Competitive Landscape

Global Vaccine Adjuvants Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Global Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route) - Industry Forecast 2024-2031

Global Vaccine Adjuvants Market Competitive Landscape

Global Vaccine Adjuvants Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Vaccine Adjuvants Market?

Who are the key vendors in the Global Vaccine Adjuvants Market?

What is the key driver of Global Vaccine Adjuvants Market?

What is the key market trend for Global Vaccine Adjuvants Market?

Which region accounted for the largest share in Global Vaccine Adjuvants Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300